Risk Factors and Prognostic Impact of Postoperative Complications in Patients with Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy

被引:10
|
作者
Yu, Hong [1 ]
Xu, Li [2 ]
Yin, Songcheng [1 ]
Jiang, Jianlong [1 ]
Hong, Chunhong [1 ]
He, Yulong [1 ]
Zhang, Changhua [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 7, Digest Dis Ctr, Shenzhen 518107, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 7, Emergency & Disaster Med Ctr, Shenzhen 518107, Peoples R China
关键词
neoadjuvant chemotherapy; postoperative complication; gastric cancer; C-REACTIVE PROTEIN; INFECTIOUS COMPLICATIONS; OPEN-LABEL; GASTRECTOMY; SURGERY; CAPECITABINE; OXALIPLATIN; SURVIVAL;
D O I
10.3390/curroncol29090511
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Neoadjuvant chemotherapy is important to improve the prognosis of patients with advanced gastric cancer. However, it may result in postoperative complications (POCs). The aim of this study is to evaluate risk factors and prognostic impact of POCs in patients receiving neoadjuvant chemotherapy. Methods: We retrospectively collected clinical information of patients who underwent curative gastrectomy after receiving neoadjuvant chemotherapy between 2011 and 2018. Overall survival (OS) was analyzed using the Kaplan-Meier method. Logistic regression and Fisher's exact test were used to evaluate risk factors for complications. Results: A total of 176 patients were included in our study. The 3-year OS rates for the complication group (n = 30) and non-complication group (n = 146) were 36.7% and 52.7%, respectively (p = 0.0294). Age, BMI, multivisceral resection and operation time were independent risk factors for POCs in patients. Patients with multivisceral resection were more likely to suffer from grade III-IV complications (p = 0.026). Inflammation complications might occur in patients with high BMI (p = 0.017). Low preoperative albumin seemed to be a risk factor for leakage complications (p = 0.033). Conclusions: Our study revealed that patients with POCs had a poor prognosis and we identified the risk factors for complications so that POCs can be avoided in time.
引用
收藏
页码:6496 / 6507
页数:12
相关论文
共 50 条
  • [21] Prognostic Value of Systemic Inflammatory Response Markers in Patients Undergoing Neoadjuvant Chemotherapy and Gastrectomy for Advanced Gastric Cancer in the Eastern European Population
    Pikula, Agnieszka
    Skorzewska, Magdalena
    Pelc, Zuzanna
    Mlak, Radoslaw
    Geca, Katarzyna
    Sedlak, Katarzyna
    Cisel, Bogumila
    Kwietniewska, Magdalena
    Rawicz-Pruszynski, Karol
    Polkowski, Wojciech P.
    CANCERS, 2022, 14 (08)
  • [22] Prediction model of objective response after neoadjuvant chemotherapy in patients with locally advanced gastric cancer
    Xu, Wei
    Fan, Zhiyuan
    Wang, Lingquan
    He, Changyu
    Ni, Zhentian
    Hua, Zichen
    Zhu, Zhenglun
    Yang, Zhongyin
    Zheng, Yanan
    Feng, Runhua
    Yan, Chao
    Li, Chen
    Yao, Xuexin
    Chen, Mingmin
    Yan, Min
    Zhu, Zhenggang
    Liu, Wentao
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (03): : 1568 - 1579
  • [23] Prognostic Impact of Fluorescent Lymphography on Gastric Cancer After Neoadjuvant Chemotherapy
    Tang, Yi-Hui
    Huang, Ze-Ning
    Sun, Yu-Qin
    Zhao, Ya-Qi
    Qiu, Wen-Wu
    He, Ji-Xun
    Li, Ping
    Xie, Jian-Wei
    Wang, Jia-Bin
    Chen, Qi-Yue
    Cao, Long-Long
    Zheng, Chao-Hui
    Lin, Jian-Xian
    Yan, Su
    Huang, Chang-Ming
    JAMA SURGERY, 2025,
  • [24] Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
    Hu, Shen-Bao
    Liu, Chun-Hao
    Wang, Xiang
    Dong, Yun-Wei
    Zhao, Lin
    Liu, Hong-Feng
    Cao, Yue
    Zhong, Ding-Rong
    Liu, Wei
    Li, Yan-Long
    Gao, Wei-Sheng
    Bai, Chun-Mei
    Shang, Zhong-Hua
    Li, Xiao-Yi
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2019, 17 (1)
  • [25] Indications for neoadjuvant treatment based on risk factors for poor prognosis before and after neoadjuvant chemotherapy alone in patients with locally advanced rectal cancer
    Ogura, Atsushi
    Uehara, Kay
    Aiba, Toshisada
    Sando, Masanori
    Tanaka, Aya
    Ohara, Noriaki
    Murata, Yuki
    Sato, Yusuke
    Hattori, Norifumi
    Nakayama, Goro
    Ebata, Tomoki
    Kodera, Yasuhiro
    Nagino, Masato
    EJSO, 2021, 47 (05): : 1005 - 1011
  • [26] FACTORS PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC CANCER
    Yildirim, Emine
    Bektas, Sibel
    Goktas Aydin, Sabin
    Er, Ahmet Muzaffer
    Yanik, Irem
    Gumuskaya, Perihan Ozkan
    Yilmaz, Barbaros Utku
    Bilici, Ahmet
    Oncel, Mustafa
    JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2022, 85 (01): : 41 - 50
  • [27] Comparison of postoperative complications in advanced head and neck cancer patients receiving neoadjuvant chemotherapy followed by surgery versus surgery alone
    Joshi, Poonam
    Joshi, Amit
    Prabhash, Kumar
    Noronha, Vanita
    Chaturvedi, Pankaj
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2015, 36 (04) : 249 - 254
  • [28] FACTORS PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC CANCER
    Yildirim, Emine
    Bektas, Sibel
    Goktas Aydin, Sabin
    Muzaffer, Ahmet E. R.
    Yanik, Irem
    Gumuskaya, Perihan Ozkan
    Yilmaz, Barbaros Utku
    Bilici, Ahmet
    Oncel, Mustafa
    JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2022,
  • [29] Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study
    Wang, Xue
    Huang, Jinxiang
    Huang, He
    Liu, Yang
    Ji, Chao
    Liu, Jian
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (4) : 579 - 586
  • [30] Combined systemic inflammatory immune index and prognostic nutrition index as chemosensitivity and prognostic markers for locally advanced gastric cancer receiving neoadjuvant chemotherapy: a retrospective study
    Ding, Ping'an
    Yang, Jiaxuan
    Wu, Jiaxiang
    Wu, Haotian
    Sun, Chenyu
    Chen, Shuya
    Yang, Peigang
    Tian, Yuan
    Guo, Honghai
    Liu, Yang
    Meng, Lingjiao
    Zhao, Qun
    BMC CANCER, 2024, 24 (01)